Literature DB >> 20832221

Quantification of aortic valve area at 256-slice computed tomography: comparison with transesophageal echocardiography and cardiac catheterization in subjects with high-grade aortic valve stenosis prior to percutaneous valve replacement.

Oliver Klass1, Matthew J Walker, Mark E Olszewski, Johannes Bahner, Sebastian Feuerlein, Martin H K Hoffmann, Alexandra Lang.   

Abstract

PURPOSE: The purpose of this study was to compare planimetric aortic valve area (AVA) measurements from 256-slice CT to those derived from transesophageal echocardiography (TEE) and cardiac catheterization in high-risk subjects with known high-grade calcified aortic stenosis. METHODS AND MATERIALS: The study included 26 subjects (10 males, mean age: 79±6; range, 61-88 years). All subjects were clinically referred for aortic valve imaging prior to percutaneous aortic valve replacement from April 2008 to March 2009. Two radiologists, blinded to the results of TEE and cardiac catheterization, independently selected the systolic cardiac phase of maximum aortic valve area and independently performed manual CT AVA planimetry for all subjects. Repeated AVA measurements were made to establish CT intra- and interobserver repeatability. In addition, the image quality of the aortic valve was rated by both observers. Aortic valve calcification was also quantified.
RESULTS: All 26 subjects had a high-grade aortic valve stenosis (systolic opening area <1.0 cm(2)) via CT-based planimetry, with a mean AVA of 0.62±0.18. In four subjects, TEE planimetry was precluded due to severe aortic valve calcification, but CT-planimetry was successfully performed with a mean AVA of 0.46±0.23 cm(2). Mean aortic valve calcium mass score was 563.8±526.2 mg. Aortic valve area by CT was not correlated with aortic valve calcium mass score. A bias and limits of agreement among CT and TEE, CT and cardiac catheterization, and TEE and cardiac catheterization were -0.07 [-0.37 to 0.24], 0.03 [-0.49 to 0.55], 0.12 [-0.39 to 0.63]cm(2), respectively. Differences in AVA among CT and TEE or cardiac catheterization did not differ systematically over the range of measurements and were not correlated with aortic valve calcium mass score.
CONCLUSION: Planimetric aortic valve area measurements from 256-slice CT agree well with those derived from TEE and cardiac catheterization in high-risk subjects with known high-grade calcified aortic stenosis.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20832221     DOI: 10.1016/j.ejrad.2010.07.015

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Non-contrast-enhanced magnetic resonance angiography is equal to contrast-enhanced multislice computed tomography for correct aortic sizing before transcatheter aortic valve implantation.

Authors:  Peter Bernhardt; Christoph Rodewald; Julia Seeger; Birgid Gonska; Dominik Buckert; Michael Radermacher; Vinzenz Hombach; Wolfgang Rottbauer; Jochen Wöhrle
Journal:  Clin Res Cardiol       Date:  2015-09-22       Impact factor: 5.460

Review 2.  Multimodality Imaging in Aortic Stenosis.

Authors:  Sabir Abdul Karim; Sherif Mahmoud Helmy
Journal:  Heart Views       Date:  2022-05-16

3.  The clinical anatomy and pathology of the human arterial valves: implications for repair or replacement.

Authors:  Michael G Bateman; Alexander J Hill; Jason L Quill; Paul A Iaizzo
Journal:  J Cardiovasc Transl Res       Date:  2013-01-17       Impact factor: 4.132

Review 4.  The contemporary role of echocardiography in the assessment and management of aortic stenosis.

Authors:  Takeshi Kitai; Rayji S Tsutsui
Journal:  J Med Ultrason (2001)       Date:  2019-12-02       Impact factor: 1.314

5.  Semiautomatic, Quantitative Measurement of Aortic Valve Area Using CTA: Validation and Comparison with Transthoracic Echocardiography.

Authors:  V Tuncay; N Prakken; P M A van Ooijen; R P J Budde; T Leiner; M Oudkerk
Journal:  Biomed Res Int       Date:  2015-06-29       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.